nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Delamanid/linezolid

QTc prolongation, leucopenia and bone marrow suppression: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Okumura M, et al. EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL. Kekkaku 91: 699-702, No. 11, Nov 2016. Available from: URL: https://www.ncbi.nlm.nih.gov/pubmed/30648372 [Japanese; summarised from a translation] - Japan

Titel: Delamanid/linezolid
QTc prolongation, leucopenia and bone marrow suppression: 3 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63680-0

Hydroxycarbamide

Case report

Tocilizumab

Case report

Paracetamol overdose

Case report

Increased stroke risk in elderly with neurotransmitter inhibitors

Clinical study

Sorafenib

Case report

Ganciclovir

Case report

Springer Medizin

Delamanid/linezolid

QTc prolongation, leucopenia and bone marrow suppression: 3 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Hydroxycarbamide

Tocilizumab

Paracetamol overdose

Increased stroke risk in elderly with neurotransmitter inhibitors

Sorafenib

Ganciclovir

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Hydroxycarbamide

Tocilizumab

Paracetamol overdose

Increased stroke risk in elderly with neurotransmitter inhibitors

Sorafenib

Ganciclovir